Please ensure Javascript is enabled for purposes of website accessibility

Why AnaptysBio Plummeted Today

By Eric Volkman - Updated Mar 8, 2021 at 5:47PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's leading drug candidate failed to meet its primary endpoint in a phase 2 clinical trial.

What happened

Tech investors who are glum about the recent performances of their holdings have nothing on AnaptysBio (ANAB 2.60%). The clinical-stage biotech's shares fell off a cliff on Monday, dropping nearly 34% on very discouraging news about a clinical study.

So what

AnaptysBio announced that its leading pipeline drug, imsidolimab, had failed to meet its primary endpoint in a phase 2 trial for the treatment of moderate to severe palmoplantar pustulosis (PPP). This is a rare autoimmune disease in which individuals experience blisters on the palms of their hands or the soles of their feet. No cure currently exists; it can only be treated.

Doctor writing on a patient medical chart.

Image source: Getty Images.

While imsidolimab was generally well-tolerated and produced no severe or adverse events in the 59-participant study, it did not sufficiently reduce the severity of the disease's symptoms. The trial was conducted at sites in both North America and Europe.

All is not lost for AnaptysBio or imsidolimab, however. The company said in the press release announcing the results that it will continue to develop the drug as a potential treatment for five other immuno-dermatological indications. Among these are acne and ichthyosis, a set of afflictions that produce dry, scaly skin.

"We look forward to multiple additional clinical readouts during 2021 and 2022," said CEO Hamza Suria.

Now what

It hurts when a biotech abandons its most promising clinical program, so Monday's AnaptysBio sell-off is entirely understandable. It will take some time for investors to regain confidence in this company.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AnaptysBio Stock Quote
AnaptysBio
ANAB
$20.88 (2.60%) $0.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.